Hastalıkların Tedavisinde Umut Vadeden Yeni Hedef: FOXO Transkripsiyon Faktörleri
Öz
Anahtar Kelimeler
Kaynakça
- 1. Referans1. Kaestner KH, Knochel W, & Martinez DE. Unified nomenclature for the winged helix/forkhead transcription factors. Genes & development, 2000; 14(2), 142–146.
- 2. Referans2. Lee S, Dong HH. FoxO integration of insulin signaling with glucose and lipid metabolism. The Journal of endocrinology, 2017; 233(2), R67–R79.
- 3. Referans3. Brown AK, Webb AE. Regulation of FOXO Factors in Mammalian Cells. Current topics in developmental biology, 2018; 127, 165–192.
- 4. Referans4. Lu H, & Huang, H. FOXO1: a potential target for human diseases. Current drug targets, 2011; 12(9), 1235–1244.
- 5. Referans5. Webb AE, Pollina EA, Vierbuchen T, Urbán N, et al. FOXO3 shares common targets with ASCL1 genome-wide and inhibits ASCL1-dependent neurogenesis. Cell reports, 2013; 4(3), 477–491.
- 6. Referans6. Huang H, Tindall J. Dynamic FoxO transcription factors. J Cell Sci, 2007; 120 (15): 2479–2487.
- 7. Referans7. Wang Z, Yu T, Huang P. Post-translational modifications of FOXO family proteins (Review). Molecular medicine reports, 2016; 14(6), 4931–4941.
- 8. Referans8. Wang F, Chan CH, Chen K, Guan X, et al. Deacetylation of FOXO3 by SIRT1 or SIRT2 leads to Skp2-mediated FOXO3 ubiquitination and degradation. Oncogene, 2012; 31(12), 1546–1557.
Ayrıntılar
Birincil Dil
Türkçe
Konular
Sağlık Kurumları Yönetimi
Bölüm
Derleme
Yazarlar
Nihal Vuranok
*
0000-0003-1020-1976
Türkiye
Yayımlanma Tarihi
3 Nisan 2022
Gönderilme Tarihi
25 Şubat 2022
Kabul Tarihi
13 Nisan 2022
Yayımlandığı Sayı
Yıl 2022 Cilt: 2 Sayı: 1